Navigation Links
Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Date:10/3/2007

WIXOM, Mich., Oct. 3 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end- stage-renal-disease market (ESRD), announced today that it has begun dosing patients in its Phase IIb Dose-Ranging Clinical Study for Soluble Ferric Pyrophosphate (SFP), the Company's physiological iron-maintenance-therapy drug.

The Phase IIb Clinical Design is a double-blind, multi-center, randomized, placebo-controlled, nine-month study consisting of up to 130 patients at multiple dialysis centers in the United States. The primary end points of the study are to evaluate SFP at varying dosage levels in hemodialysis patients and to determine the optimal concentration of SFP in dialysate that will maintain iron balance within their target hemoglobin range. Secondary end points include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic infection episodes and to quantify the amount of SFP iron transferred from the dialysate directly to the blood during the dialysis session.

Robert L. Chioini, Chairman and CEO of Rockwell stated, "Beginning the successful dosing of dialysis patients is another significant milestone in our clinical path for gaining FDA market approval for SFP. Going forward, we anticipate sharing news of our clinical progress as it becomes available."

About Soluble Ferric Pyrophosphate (SFP)

Rockwell's proprietary iron-delivery product, SFP, is a soluble form of iron designed to provide physiological iron- maintenance therapy in ESRD patients by delivering iron via dialysate during dialysis treatments. SFP
'/>"/>

SOURCE Rockwell Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Asterias ... U.S. Food and Drug Administration (FDA) to initiate a ... patients with complete cervical spinal cord injury.  The approved ... clinical study of the product, and is designed to ... in patients with complete cervical spinal cord injuries, the ...
(Date:8/26/2014)... Aug. 26, 2014  Kewaunee Scientific Corporation (Nasdaq: ... quarter ended July 31, 2014. Sales for ... $32,003,000 in the first quarter last year. Net earnings ... share, as compared to net earnings of $1,587,000, or ... the prior year. However, both sales and earnings in ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... two fidaxomicin Phase 3 trials in patients with ... Meeting of the Infectious Disease Society of America (IDSA) ... investigator Derrick Crook, M.D., of the University of Oxford, ...
... leading home health care and hospice company (Nasdaq: AMED ... home care in this week,s issue of the New England Journal ... Advisory Board. Titled, "Why Health Care is Going ... home care as an increasingly crucial component of America,s health care ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:8/27/2014)... to market research report, “Variable Frequency Drives Market by ... High), Voltage (Low & Medium), Application (Pump, Fan, Compressor, ... & Forecast to 2019” defines and segments the global ... of the market size. The variable frequency drives market ... to $22.73 billion by 2019, with a CAGR of ...
(Date:8/27/2014)... 27, 2014 Specialty Technical Publishers (STP) ... International Audit Protocol Consortium (IAPC) EHS audit protocol for ... around the world use IAPC EHS audit protocols to ... rapidly collect, share, archive, and export audit findings in ... are prepared by AECOM in partnership with STP and ...
(Date:8/27/2014)... Main Street Dental Team ( MainStreetDentalTeam.com ), ... how long a toothbrush can be used before it has ... teeth and gums. , “Replacing a toothbrush is something that ... Dr. Harvey Schwartz, owner of Main Street Dental Team. “Using ... months." , Dr. Schwartz explains that what’s important to keep ...
(Date:8/27/2014)... Top10inaction, a professional website reveals the best ... by name brands such as Apple, Samsung, Sony, Blackberry ... means a lot more than just a device of ... surf the internet with their little toys. And just ... to choose a right smartphone has become a dilemma. ...
(Date:8/27/2014)... DC (PRWEB) August 27, 2014 ... Diplomat University were announced as the winners of ... August issue of Atlantic Information Services, Inc.’s ... penned by the company’s founder and Principal Consultant ... were commended for meeting the true definition of ...
Breaking Medicine News(10 mins):Health News:Variable Frequency Drives Market Worth $22.73 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 2Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 3Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 4Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Advises on the Best Time to Replace a Toothbrush 2Health News:Best Smartphones 2014 Revealed by Top10InAction.com 2Health News:Specialty Pharmacy Solutions Founder Reveals Winners of Innovation Competition in August Issue of AIS Newsletter 2Health News:Specialty Pharmacy Solutions Founder Reveals Winners of Innovation Competition in August Issue of AIS Newsletter 3
... Will Highlight Hurdles To Government Oversight & Gaining ... ... Without an improved,governance structure, the benefits of nanotechnology may be difficult ... David Rejeski, director of the Project on Emerging,Nanotechnologies (PEN). Rejeski testifies ...
... 10,000 University of California RNs to ... Bargain Over Improved Patient Safety, OAKLAND, ... the California Nurses Association/National Nurses Organizing,Committee today won a major ... nurses it represents to strike, and to,bargain over improved staffing ...
... Fla., April 22 PainCare Holdings,Inc. (Amex: PRZ ... services, today announced that it received a letter from ... notifying the Company that,its delay in filing its Form ... a failure to comply with the continued listing standards,set ...
... 22 Cardica, Inc.,(Nasdaq: CRDC ) today announced ... quarter ended March 31, 2008, on Tuesday, April 29, ... host a,conference call at 4:30 p.m. Eastern Time to ... company,s business., Conference Call Details, To access ...
... (Nasdaq: UAHC ) today announced that the ... Tennessee, Bureau of TennCare,(,TennCare,), today publicly disclosed its ... organizations, not including the company,s,subsidiary, UAHC Health Plan ... of TennCare,s selection process pursuant to its Request ...
... use of cisplatin no better than standard treatment, researchers ... Compared to the standard treatment regimen for anal canal ... other treatments didn,t improve disease-free survival and resulted in ... study. , Currently, the preferred primary therapy for patients ...
Cached Medicine News:Health News:Improved Governance Needed To Realize Nanotech's Benefits 2Health News:CNA/NNOC Wins Key Legal Decision Protecting Right of Public Employees to Strike 2Health News:PainCare Receives Notices From American Stock Exchange 2Health News:PainCare Receives Notices From American Stock Exchange 3Health News:PainCare Receives Notices From American Stock Exchange 4Health News:Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008 2Health News:United American Healthcare Corporation Provides Update on TennCare RFP Awards 2Health News:New Anal Cancer Therapy Fails to Improve Outcomes 2
Inquire...
... damaged fiber optics reduce the light output to ... in the optical clarity that is so vital. ... essential to prevent further damage and more extensive ... can inspect your cables for you at no ...
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
Medicine Products: